Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

June 30, 2021

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG

Placebo

Administered as specified in the treatment arm.

DRUG

BIIB061

Administered as specified in the treatment arm.

BIOLOGICAL

Interferon-beta1

Stable dose as prescribed by the physician.

DRUG

Glatiramer acetate

Stable dose as prescribed by the physician.